Trump Picks National Cancer Institute Director

Ned Sharpless currently leads the cancer center at the University of North Carolina, Chapel Hill.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

BRIAN STRICKLAND/LINEBERGER COMPREHENSIVE CANCER CENTER Update (October 18): Sharpless was sworn in as NCI director today.

President Donald Trump has selected Ned Sharpless, a physician in charge of the cancer center at the University of North Carolina, Chapel Hill, to lead the National Cancer Institute (NCI). The nomination received praise from the cancer research community.

Margaret Foti, the chief scientific officer of the American Association for Cancer Research, says in a statement she is “absolutely thrilled” by Trump’s choice. “[Sharpless’s] enthusiasm for innovative scientific methods and ideas, as well as his appreciation for the value and importance of basic research to advancing translational discoveries, will allow the NCI to continue leading the way in programs aimed at preventing disease, improving health, and reducing suffering from cancer, while also helping to maintain America’s edge in the life sciences.”

Sharpless’s group studies cellular ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies